Drug intelligence / Profile preview

docetaxel + obatoclax mesylate

Development stage: Unknown
Lead developer: Teva Pharmaceutical Industries
Modality: Small Molecules
Administration: Intravenous

Overview

docetaxel + obatoclax mesylate is a combination therapy investigated in clinical trials for the treatment of relapsed or refractory non-small cell lung cancer (NSCLC). Docetaxel is a taxane chemotherapy agent that disrupts microtubule function, leading to cell cycle arrest and apoptosis. Obatoclax mesylate is a pan-Bcl-2 inhibitor that antagonizes anti-apoptotic Bcl-2 family proteins, thereby promoting apoptosis and potentially enhancing the cytotoxic effects of chemotherapy. The combination was evaluated in phase 1/2 trials with the aim of improving outcomes in patients who had progressed after prior chemotherapy[1][8][3].

Other names: Obatoclax mesylate plus docetaxelGX15-070MS plus docetaxelGX-15-070MS plus docetaxelGX 15-070MS plus docetaxel

Targets

BCL-2 (BCL-2 family)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on docetaxel + obatoclax mesylate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on docetaxel + obatoclax mesylate.

Explore the full profile